LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

ThermoGenesis Develops Blood Test to Detect COVID-19 in Minutes

By LabMedica International staff writers
Posted on 06 Apr 2020
Print article
Image: SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit (Photo courtesy of ThermoGenesis Holdings, Inc.)
Image: SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit (Photo courtesy of ThermoGenesis Holdings, Inc.)
ThermoGenesis Holdings, Inc. (Rancho Cordova, CA, USA), which provides automated cell processing tools and services in the cell and gene therapy field, has developed an advanced point-of-care test that will allow rapid diagnosis of the COVID-19 virus, including asymptomatic cases, using just a single drop of blood without the need for special lab equipment and deliver results in less than 10 minutes.

ThermoGenesis develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.

ThermoGenesis’ SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit is designed to allow pre-screening for COVID-19 infections as well as identification of individuals who have encountered the virus and have developed protective immunity. Requiring just a single drop of blood, the Kit is intended for professional use and will deliver results — with no lab equipment necessary — in less than 10 minutes, at the point-of-care. The company is currently completing validations in accordance with the “Policy for Diagnostic Test for Coronavirus Disease – 2019 during the Public Health Emergency: Immediately in Effect Guidance for Clinical Laboratories, Commercial Manufacturer, and Food and Drug Administration Staff issued on March 16, 2020 for Serological Diagnostics.” ThermoGenesis will notify the FDA upon completion of validation prior to product launch.

“The company has been in discussions with healthcare distributors, healthcare institutions, medical practitioners and government agencies, and is working quickly to bring the COVID-19 Test Kits to the US professional medical community,” said Chris Xu, Ph.D, Chief Executive Officer of ThermoGenesis. “This Kit will not only allow pre-screening for COVID-19 infections, but will also allow identification of individuals who have encountered the virus and have developed protective immunity. This will be essential in expediting the safety required to get the nation back to work in the future.”

Related Links:
ThermoGenesis Holdings, Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS-CoV-2 Test
One Step SARS-CoV-2 Nucleic Acid Detection Kit (P761H)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more